TTK and neoplasm: In a human cancer mouse model, oral administration of the TTK inhibitor cfi-402257 alone or in combination with an anti-programmed cell death 1 (PD-1) antibody inhibited tumor growth at a well-tolerated dose (Mason et al. 2017).